![]() Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including results of the clinical trial. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of psilocin as compared to psilocybin. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward-looking statements or information. Learn more at and on Twitter, Instagram and LinkedIn.Ĭertain statements and information contained herein may constitute "forward-looking statements" and "forward-looking information," respectively, under Canadian securities legislation. ![]() Filament is headquartered in Vancouver, British Columbia and trades on the OTCQB Venture Market (OTCQB: FLHLF), Canada's NEO Exchange (NEO:FH), and the Frankfurt Stock Exchange (FSE:7QS). Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, and its subsidiary Psilo Scientific's in-house GMP facility, and Health Canada Dealer's License for all natural psychedelics. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world's mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. įilament Health is an exclusively-natural psychedelic drug discovery and extraction technology company. ![]() "The oral and sublingual administration presents an opportunity to learn about psilocin's effects compared to psilocybin and perhaps set a new standard for psychedelic assisted therapy."įurther information about the history and benefits of psilocin can be found at. Josh Woolley, MD/Ph.D., Director of TrPR and the study's Principal Investigator. "My team and I are very excited to begin dosing Filament's drug candidates in our clinic," said Dr. To date, synthetic manufacturers have been unable to produce a stable formulation of psilocin and enter it into a clinical trial. In addition, psilocin is an ideal candidate for sublingual delivery because of the bypassing of the gut, where the conversion to psilocybin is thought to primarily occur. These potential attributes are being studied in the authorized trial. As a result of the need for psilocybin to convert into psilocin before becoming active in the human body, the direct administration of psilocin may yield several therapeutic benefits such as faster onset time, greater consistency, increased bioavailability, and lessened side effects. The phase 1 trial has been designed to include 20 healthy subjects and will examine the effects of Filament's three proprietary botanical drug candidates: PEX010 (oral psilocybin), PEX020 (oral psilocin), and PEX030 (sublingual psilocin). Our candidates enjoy significant IP protection, unlike most other psychedelics currently under clinical investigation." "Our innovative technology has allowed us to create IP-protected botanical drug candidates of oral psilocin, sublingual psilocin, and oral psilocybin, and to enter them into an FDA-approved natural psychedelic clinical trial. ![]() "We are excited to announce this milestone as validation of our ability to cultivate variable psychedelic biomass and transform it into pharmaceutical-grade drug candidates," said Chief Executive Officer, Benjamin Lightburn.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |